Abstract: A valve leakage system includes a first pressure sensor, a high pressure shut off valve (HPSOV) downstream of the first pressure sensor, and a manifold downstream of the HPSOV. A second pressure sensor is in communication with the manifold; a system component (such as a lower pressure valve) is downstream of the manifold; and a duct is between the system component and the manifold. An exhaust area (such as a hole) is in one of the duct, the manifold, and the system component. A comparator unit compares pressure between the first and second pressure sensors to enable the detection of a leak in the HPSOV. The sizing of the exhaust area is established to differentiate between an allowable HPSOV leakage and a leakage indicative of a failure requiring maintenances or replacement.

Abstract: A problem generator that takes an input as a math problem, analyzes the math problem, and intelligently spawns similar example problem types. The output is a set of math problems based on the conditions set during analysis and customization. For example, if the original problem deals with linear equations, this will be detected during analysis and used to spawn other linear equations as problems. Moreover, if the answer to the original problem is in integer format, so will the answers to the spawned problems. A customizable UI is designed to allow further customization of problem conditions to generate an accurate set of problems based on the initial input. Problem generator templates can be created, shared and modified for distribution and/or future use. Additionally, problem generation APIs can be extended for external code to automate and consume generated math problems.

Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.

Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a-moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.

Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.

Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.

Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a-moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.

Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.

Abstract: Potassium impurity is removed from ammonium molybdate by dissolving the ammonium molybdate in hot acid, allowing the acid solution to cool whereby the ammonium molybdate precipitates out of the solution as molybdenum trioxide and then separating, washing and drying the molybdenum trioxide.

Abstract: A method is disclosed for removing carbon from the surface of a cemented tungsten carbide article which comprises contacting a cemented tungsten carbide article with an aqueous solution of hydrogen peroxide having a concentration of at least about 5% by volume hydrogen perioxide for a sufficient length of time to remove the major portion of the carbon from the surfaces of the article.

Abstract: A method is disclosed for removing iron from iron-contaminated sulfuric acid to render the sulfuric acid suitable for ion membrane processing which comprises contacting the iron-contaminated sulfuric acid with an oxidizing agent to oxidize essentially all of the iron to the +3 oxidation state, contacting the resulting iron-contaminated sulfuric acid containing oxidized iron with a complexing agent which can be citric acid, oxalic acid, and tartaric acid, with the amount of the complexing agent being sufficient to complex essentially all of the oxidized iron, and contacting the resulting iron-contaminated sulfuric acid containing the complexed iron with activated carbon to remove essentially all of the iron and produce a purified sulfuric acid solution.